GOLD BOARD OF DIRECTORS (2016)
Alvar Agusti, MD, Chair
Hospital Clinic, Universitat de Barcelona, Ciberes
Barcelona, Spain

Marc Decramer, MD, Chair (to 05/16)
University of Leuven
Leuven, Belgium

Bartolome R. Celli, MD
Brigham and Women's Hospital Boston,
Massachusetts, USA

Rongchang Chen, MD
Guangzhou Institute of Respiratory Disease
Guangzhou, PRC

Gerard Criner, MD
Temple University School of Medicine
Philadelphia, Pennsylvania, USA

Peter Frith, MD
Repatration General Hospital, Adelaide
South Australia, Australia

David Halpin, MD
Royal Devon and Exeter Hospital
Devon, UK

M. Victorina López Varela, MD
Universidad de la República Montevideo,
Uruguay

Masaharu Nishimura, MD
Hokkaido University School of Medicine Sapporo,
Japan

Robert Rodriguez-Roisin, MD
Hospital Clinic, Universitat de Barcelona
Barcelona, Spain

Claus Vogelmeier, MD
University of Gießen and Marburg
Marburg, Germany

GOLD PROGRAM DIRECTOR
Rebecca Decker, MSJ
Fontana, Wisconsin, USA

Suzanne S. Hurd, PhD (until 12/2015)
Vancouver, Washington, USA

EDITORIAL ASSISTANCE
Ruth Hadfield, PhD
Sydney, Australia

GOLD NATIONAL LEADERS
The GOLD Board of Directors is grateful to the many GOLD
National Leaders who participated in discussions of
concepts that appear in GOLD reports.

INVITED CONTRIBUTORS
Prof. Richard Beasley, NZ; Peter M A Calverley, MD, UK;
Ciro Casanova, MD, Spain; James Donohue, MD, USA;
MeiLin Han, MD, USA; Nicola Hanania, MBBS, USA;
Maria Montes de Oca, MD, Venezuela; Takahide Nagase,
MD, Japan; Alberto Papi, MD, Italy; Ian Pavord, MD, UK;
David Price, FRCGP, UK.

GOLD SCIENCE COMMITTEE* (2016)
Claus Vogelmeier, MD, Chair
University of Marburg
Marburg, Germany

Alvar Agusti, MD
Hospital Clinic, Universitat de Barcelona, Ciberes,
Barcelona, Spain

Antonio Anzueto, MD
University of Texas Health Science Center
San Antonio, Texas, USA

Peter Barnes, MD
National Heart and Lung Institute
London, United Kingdom

Jean Bourbeau, MD
McGill University Health Centre
Montreal, Canada

Gerard Criner, MD
Temple University School of Medicine
Philadelphia, Pennsylvania, USA

Leonardo M. Fabbri, MD
University of Modena & Reggio Emilia
Modena, Italy

Fernando Martinez, MD
University of Michigan School of Medicine
Ann Arbor, Michigan, USA

Nicolas Roche, MD
Hôpital Cochin
Paris, France

Robert Stockley, MD
University Hospital
Birmingham, UK

Jørgen Vestbo, MD
University of Manchester
Manchester, England, UK

Jadwiga A. Wedzicha, MD
University College London
London, UK

* Disclosure forms for GOLD Committees are posted on the
GOLD Website, www.goldcopd.org
# TABLE OF CONTENTS

**TABLE OF CONTENTS** ......................................................... IV

**GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD** ...... 1

- **INTRODUCTION** .................................................... 1
- **DEFINITION AND OVERVIEW** .................................. 1
  - OVERALL KEY POINTS: ........................................ 1
  - WHAT IS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)? ..................... 2
  - WHAT CAUSES COPD? .......................................... 2
- **DIAGNOSIS AND ASSESSMENT OF COPD** .................. 4
  - OVERALL KEY POINTS: ........................................ 4
  - DIAGNOSIS ........................................................ 4
  - DIFFERENTIAL DIAGNOSIS ................................... 5
  - ASSESSMENT ...................................................... 5
    - Classification of severity of airflow obstruction ...................................... 6
    - Assessment of symptoms ....................................... 6
    - Revised combined COPD assessment ......... 7
- **EVIDENCE SUPPORTING PREVENTION AND MAINTENANCE THERAPY** .................. 9
  - OVERALL KEY POINTS: ........................................ 9
  - SMOKING CESSATION .......................................... 10
  - VACCINATIONS .................................................. 10
    - Influenza vaccine ........................................... 10
    - Pneumococcal vaccine ..................................... 10
  - PHARMACOLOGIC THERAPY FOR STABLE COPD ........................................... 11
    - Bronchodilators ............................................ 11
    - Beta-agonists .............................................. 11
    - Antimuscarinic drugs ..................................... 11
    - Methylxanthines ........................................... 12
    - Combination bronchodilator therapy .......... 12
    - Anti-inflammatory agents ............................... 14
    - Inhaled corticosteroids (ICS) ....................... 14
    - Issues related to inhaled delivery ........... 16
    - Other pharmacologic treatments ............. 16
  - REHABILITATION, EDUCATION & SELF-MANAGEMENT ....................................... 17
    - Pulmonary rehabilitation ................................. 17
  - SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE ................................ 17
    - Symptom control and palliative care .......... 17
  - OTHER TREATMENTS ............................................ 18
  - Oxygen therapy and ventilatory support ......... 18
- **MANAGEMENT OF STABLE COPD** .................................. 20
  - OVERALL KEY POINTS: ........................................ 20
  - IDENTIFY AND REDUCE EXPOSURE TO RISK FACTORS .................................. 20
  - TREATMENT OF STABLE COPD ................................. 21
    - PHARMACOLOGIC TREATMENT ................................ 21
    - Pharmacologic treatment algorithms .......... 23
    - MONITORING AND FOLLOW-UP ............................. 25
- **MANAGEMENT OF EXACERBATIONS** ................................ 26
  - OVERALL KEY POINTS: ........................................ 26
  - TREATMENT OPTIONS ........................................... 27
    - Treatment Setting .......................................... 27
    - Respiratory Support .............................. ........ 29
  - HOSPITAL DISCHARGE AND FOLLOW-UP ........................... 30
- **COPD AND COMORBIDITIES** ....................................... 32
  - OVERALL KEY POINTS: ........................................ 32
  - REFERENCES ..................................................... 33

**COPYRIGHTED MATERIAL—DO NOT COPY OR DISTRIBUTE**
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD

INTRODUCTION

Obstructive Pulmonary Disease (COPD) represents an important public health challenge and is a major cause of chronic morbidity and mortality throughout the world. COPD is currently the fourth leading cause of death in the world but is projected to be the 3rd leading cause of death by 2020. More than 3 million people died of COPD in 2012 accounting for 6% of all deaths globally. Globally, the COPD burden is projected to increase in coming decades because of continued exposure to COPD risk factors and aging of the population.

This Pocket Guide has been developed from the Global Strategy for the Diagnosis, Management, and Prevention of COPD (2017 Report), which aims to provide a non-biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD that can aid the clinician. Discussions of COPD and COPD management, evidence levels, and specific citations from the scientific literature are included in that source document, which is available from www.goldcopd.org. The tables and figures in this Pocket Guide follow the numbering of the 2017 Global Strategy Report for reference consistency.

DEFINITION AND OVERVIEW

OVERALL KEY POINTS:

- **Chronic Obstructive Pulmonary Disease (COPD)** is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

- The most common respiratory symptoms include dyspnea, cough and/or sputum production. These symptoms may be under-reported by patients.

- The main risk factor for COPD is tobacco smoking but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development and accelerated aging.

- COPD may be punctuated by periods of acute worsening of respiratory symptoms, called exacerbations.

- In most patients, COPD is associated with significant concomitant chronic diseases, which increase its morbidity and mortality.
WHAT IS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)?

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. The chronic airflow limitation that is characteristic of COPD is caused by a mixture of small airways disease (e.g., obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary from person to person (Figure 1.1).

WHAT CAUSES COPD?

Worldwide, the most commonly encountered risk factor for COPD is tobacco smoking. Other types of tobacco, (e.g. pipe, cigar, water pipe) and marijuana are also risk factors for COPD. Outdoor, occupational, and indoor air pollution – the latter resulting from the burning of biomass fuels – are other major COPD risk factors.

Nonsmokers may also develop COPD. COPD is the result of a complex interplay of long-term cumulative exposure to noxious gases and particles, combined with a variety of host factors including genetics, airway hyper-responsiveness and poor lung growth during childhood.

Often, the prevalence of COPD is directly related to the prevalence of tobacco smoking, although in many countries outdoor, occupational and indoor air pollution (resulting from the burning of wood
and other biomass fuels) are major COPD risk factors.\textsuperscript{6,7}

The risk of developing COPD is related to the following factors:

- **Tobacco smoke** - including cigarette, pipe, cigar, water-pipe and other types of tobacco smoking popular in many countries, as well as environmental tobacco smoke (ETS)

- **Indoor air pollution** - from biomass fuel used for cooking and heating in poorly vented dwellings, a risk factor that particularly affects women in developing countries

- **Occupational exposures** - including organic and inorganic dusts, chemical agents and fumes, are under-appreciated risk factors for COPD.\textsuperscript{6,8}

- **Outdoor air pollution** - also contributes to the lungs’ total burden of inhaled particles, although it appears to have a relatively small effect in causing COPD.

- **Genetic factors** - such as severe hereditary deficiency of alpha-1 antitrypsin (AATD).\textsuperscript{9}

- **Age and gender** - aging and female gender increase COPD risk.

- **Lung growth and development** - any factor that affects lung growth during gestation and childhood (low birth weight, respiratory infections, etc.) has the potential to increase an individual’s risk of developing COPD.

- **Socioeconomic status** - there is strong evidence that the risk of developing COPD is inversely related to socioeconomic status.\textsuperscript{10} It is not clear, however, whether this pattern reflects exposures to indoor and outdoor air pollutants, crowding, poor nutrition, infections, or other factors related to low socioeconomic status.

- **Asthma and airway hyper-reactivity** - asthma may be a risk factor for the development of airflow limitation and COPD.

- **Chronic bronchitis** - may increase the frequency of total and severe exacerbations.

- **Infections** - a history of severe childhood respiratory infection has been associated with reduced lung function and increased respiratory symptoms in adulthood.\textsuperscript{11}
DIAGNOSIS AND ASSESSMENT OF COPD

OVERALL KEY POINTS:

• COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease.

• Spirometry is required to make the diagnosis; the presence of a post-bronchodilator FEV₁/FVC < 0.70 confirms the presence of persistent airflow limitation.

• The goals of COPD assessment are to determine the severity of the disease, including the severity of airflow limitation, the impact of disease on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy.

• Concomitant chronic diseases occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, anxiety, and lung cancer. These comorbidities should be actively sought and treated appropriately when present as they can influence mortality and hospitalizations independently.

DIAGNOSIS

COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or history of exposure to risk factors for the disease. A detailed medical history of a new patient who is known, or suspected, to have COPD is essential. Spirometry is required to make the diagnosis in this clinical context; the presence of a post-bronchodilator FEV₁/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD in patients with appropriate symptoms and significant exposures to noxious stimuli. Spirometry is the most reproducible and objective measurement of airflow limitation. It is a noninvasive and readily available test. Despite its good sensitivity, peak expiratory flow measurement alone cannot be reliably used as the only diagnostic test because of its weak specificity.

Table 2.1. Key indicators for considering a diagnosis of COPD

Consider COPD, and perform spirometry, if any of these indicators are present in an individual over age 40. These indicators are not diagnostic themselves, but the presence of multiple key indicators increases the probability of a diagnosis of COPD. Spirometry is required to establish a diagnosis of COPD.

| Dyspnea that is: | Progressive over time. |
| Chronic cough: | Characteristically worse with exercise. |
| Chronic sputum production: | Persistent. |
| Recurrent wheeze. | Any pattern of chronic sputum production may indicate COPD. |
| Recurrent lower respiratory tract infections | Host factors (such as genetic factors, congenital/developmental abnormalities etc.). |
| History of risk factors: | Tobacco smoke (including popular local preparations). |
| Occupational dusts, vapors, fumes, gases and other chemicals. |
| Family history of COPD and/or childhood factors: | For example low birthweight, childhood respiratory infections etc. |
DIFFERENTIAL DIAGNOSIS

A major differential diagnosis is asthma. In some patients with chronic asthma, a clear distinction from COPD is not possible using current imaging and physiological testing techniques. In these patients, current management is similar to that of asthma. Other potential diagnoses are usually easier to distinguish from COPD (Table 2.7).

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Suggestive Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD</td>
<td>Onset in mid-life. Symptoms slowly progressive. History of tobacco smoking or exposure to other types of smoke.</td>
</tr>
<tr>
<td>Asthma</td>
<td>Onset early in life (often childhood). Symptoms vary widely from day to day. Symptoms worse at night/early morning. Allergy, rhinitis, and/or eczema also present. Family history of asthma. Obesity coexistence.</td>
</tr>
<tr>
<td>Congestive Heart Failure</td>
<td>Chest X-ray shows dilated heart, pulmonary edema. Pulmonary function tests indicate volume restriction, not airflow limitation.</td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td>Large volumes of purulent sputum. Commonly associated with bacterial infection. Chest X-ray/CT shows bronchial dilation, bronchial wall thickening.</td>
</tr>
<tr>
<td>Obliterative Bronchiolitis</td>
<td>Onset at younger age, nonsmokers. May have history of rheumatoid arthritis or acute fume exposure. Seen after lung or bone marrow transplantation. CT on expiration shows hyperdense areas.</td>
</tr>
<tr>
<td>Diffuse Panbronchiolitis</td>
<td>Predominantly seen in patients of Asian descent. Most patients are male and nonsmokers. Almost all have chronic sinusitis. Chest X-ray and HRCT show diffuse small centrilobular nodular opacities and hyperinflation.</td>
</tr>
</tbody>
</table>

These features tend to be characteristic of the respective diseases, but are not mandatory. For example, a person who has never smoked may develop COPD (especially in the developing world where other risk factors may be more important than cigarette smoking); asthma may develop in adult and even in elderly patients.

Alpha-1 antitrypsin deficiency (AATD) screening. The World Health Organization recommends that all patients with a diagnosis of COPD should be screened once especially in areas with high AATD prevalence. A low concentration (< 20% normal) is highly suggestive of homozygous deficiency. Family members should also be screened.

ASSESSMENT

The goals of COPD assessment are to determine the severity of airflow limitation, its impact on the patient’s health status and the risk of future events (such as exacerbations, hospital admissions or death), in order to, eventually, guide therapy. To achieve these goals, COPD assessment must consider the following aspects of the disease separately:

- The presence and severity of the spirometric abnormality
- Current nature and magnitude of the patient’s symptoms
- Exacerbation history and future risk
- Presence of comorbidities

**Classification of severity of airflow obstruction**

The classification of airflow limitation severity in COPD is shown in Table 2.4. Specific spirometric cut-points are used for purposes of simplicity. Spirometry should be performed after the administration of an adequate dose of at least one short-acting inhaled bronchodilator in order to minimize variability.

<table>
<thead>
<tr>
<th>GOLD 1:</th>
<th>Mild</th>
<th>FEV(_1) ≥ 80% predicted</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD 2:</td>
<td>Moderate</td>
<td>50% ≤ FEV(_1) &lt; 80% predicted</td>
</tr>
<tr>
<td>GOLD 3:</td>
<td>Severe</td>
<td>30% ≤ FEV(_1) &lt; 50% predicted</td>
</tr>
<tr>
<td>GOLD 4:</td>
<td>Very Severe</td>
<td>FEV(_1) &lt; 30% predicted</td>
</tr>
</tbody>
</table>

It should be noted that there is only a weak correlation between FEV\(_1\), symptoms and impairment of a patient's health status.\(^{15,16}\) For this reason, formal symptomatic assessment is also required.

**Assessment of symptoms**

In the past, COPD was viewed as a disease largely characterized by breathlessness. A simple measure of breathlessness such as the Modified British Medical Research Council (mMRC) Questionnaire\(^ {17}\) (Table 2.5) was considered adequate, as the mMRC relates well to other measures of health status and predicts future mortality risk.\(^ {18,19}\)

<table>
<thead>
<tr>
<th>mMRC Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>I only get breathless with strenuous exercise.</td>
</tr>
<tr>
<td>1</td>
<td>I get short of breath when hurrying on the level or walking up a slight hill.</td>
</tr>
<tr>
<td>2</td>
<td>I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level.</td>
</tr>
<tr>
<td>3</td>
<td>I stop for breath after walking about 100 meters or after a few minutes on the level.</td>
</tr>
<tr>
<td>4</td>
<td>I am too breathless to leave the house or I am breathless when dressing or undressing.</td>
</tr>
</tbody>
</table>

\(^{a}\) Fletcher CM. BMJ 1960; 2: 1662.
However, it is now recognized that COPD impacts patients beyond just dyspnea. For this reason, a comprehensive assessment of symptoms is recommended using measures such as the COPD Assessment Test (CAT)^1 (Figure 2.3) and the COPD Control Questionnaire (The CCQ)^5 have been developed and are suitable.

**Revised combined COPD assessment**

An understanding of the impact of COPD on an individual patient combines the symptomatic assessment with the patient’s spirometric classification and/or risk of exacerbations. The “ABCD” assessment tool of the 2011 GOLD update was a major advancement from the simple spirometric grading system of the earlier versions of GOLD because it incorporated patient-reported outcomes and highlighted the importance of exacerbation prevention in the management of COPD. However, there were some important limitations. Firstly, the ABCD assessment tool performed no better than the spirometric grades for mortality prediction or other important health outcomes in COPD.²¹⁻²³ Moreover, group “D” outcomes were modified by two parameters: lung function and/or exacerbation history, which caused confusion.¹⁶ To address these and other concerns (while at the same time maintaining consistency and simplicity for the practicing clinician), a refinement of the ABCD assessment tool is proposed that separates spirometric grades from the “ABCD” groups. For

---

¹ The COPD Assessment Test was developed by a multi-disciplinary group of international experts in COPD supported by GSK. COPD Assessment Test and the CAT logo is a trademark of the GlaxoSmithKline group of companies. © 2009 GlaxoSmithKline. All rights reserved. GSK activities with respect to the COPD Assessment Test are overseen by a governance board that includes independent external experts, one of whom chairs the board.
some therapeutic recommendations, ABCD groups will be derived exclusively from patient symptoms and their history of exacerbation. Spirometry in conjunction with patient symptoms and exacerbation history remains vital for the diagnosis, prognostication and consideration of other important therapeutic approaches. This new approach to assessment is illustrated in Figure 2.4.

In the refined assessment scheme, patients should undergo spirometry to determine the severity of airflow limitation (i.e., spirometric grade). They should then undergo assessment of either dyspnea using mMRC or symptoms using CAT™. Finally, their history of exacerbations (including prior hospitalizations) should be recorded.

**Example:** Consider two patients - both patients with FEV\(_1\) < 30% of predicted, CAT scores of 18 and one with no exacerbations in the past year and the other with three exacerbations in the past year. Both would have been labelled GOLD D in the prior classification scheme. However, with the new proposed scheme, the subject with 3 exacerbations in the past year would be labelled GOLD grade 4, group D; the other subject with no exacerbations would be labelled GOLD Grade 4, group B.

This classification scheme may facilitate consideration of individual therapies (exacerbation prevention versus symptom relief as outlined in the above example) and also help guide escalation and de-escalation therapeutic strategies for a specific patient.
## EVIDENCE SUPPORTING PREVENTION AND MAINTENANCE THERAPY

### OVERALL KEY POINTS:

- **Smoking cessation is key.** Pharmacotherapy and nicotine replacement reliably increase long-term smoking abstinence rates.

- **The effectiveness and safety of e-cigarettes as a smoking cessation aid is uncertain at present.**

- **Pharmacologic therapy can reduce COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance.**

- **Each pharmacologic treatment regimen should be individualized and guided by the severity of symptoms, risk of exacerbations, side-effects, comorbidities, drug availability and cost, and the patient’s response, preference and ability to use various drug delivery devices.**

- **Inhaler technique needs to be assessed regularly.**

- **Influenza vaccination decreases the incidence of lower respiratory tract infections.**

- **Pneumococcal vaccination decreases lower respiratory tract infections.**

- **Pulmonary rehabilitation improves symptoms, quality of life, and physical and emotional participation in everyday activities.**

- **In patients with severe resting chronic hypoxemia, long-term oxygen therapy improves survival.**

- **In patients with stable COPD and resting or exercise-induced moderate desaturation, long-term oxygen treatment should not be prescribed routinely. However, individual patient factors must be considered when evaluating the patient’s need for supplemental oxygen.**

- **In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, long-term non-invasive ventilation may decrease mortality and prevent re-hospitalization.**

- **In select patients with advanced emphysema refractory to optimized medical care, surgical or bronchoscopic interventional treatments may be beneficial.**

- **Palliative approaches are effective in controlling symptoms in advanced COPD.**
SMOKING CESSATION

Smoking cessation has the greatest capacity to influence the natural history of COPD. If effective resources and time are dedicated to smoking cessation, long-term quit success rates of up to 25% can be achieved.24

A five-step program for intervention (Table 3.1)25-27 provides a helpful strategic framework to guide health care providers interested in helping their patients stop smoking.25,27,28

<table>
<thead>
<tr>
<th>Table 3.1. Brief strategies to help the patient willing to quit</th>
</tr>
</thead>
<tbody>
<tr>
<td>• ASK: Systematically identify all tobacco users at every visit.</td>
</tr>
<tr>
<td>- Implement an office-wide system that ensures that, for EVERY patient at EVERY clinic visit, tobacco-use status is queried and documented.</td>
</tr>
<tr>
<td>• ADVISE: Strongly urge all tobacco users to quit.</td>
</tr>
<tr>
<td>- In a clear, strong, and personalized manner, urge every tobacco user to quit.</td>
</tr>
<tr>
<td>• ASSESS: Determine willingness and rationale of patient's desire to make a quit attempt.</td>
</tr>
<tr>
<td>- Ask every tobacco user if he or she is willing to make a quit attempt at this time (e.g., within the next 30 days).</td>
</tr>
<tr>
<td>• ASSIST: Aid the patient in quitting.</td>
</tr>
<tr>
<td>- Help the patient with a quit plan; provide practical counseling; provide in-treatment social support; help the patient obtain extra-treatment social support; recommend use of approved pharmacotherapy except in special circumstances; provide supplementary materials.</td>
</tr>
<tr>
<td>• ARRANGE: Schedule follow-up contact.</td>
</tr>
<tr>
<td>- Schedule follow-up contact, either in person or via telephone.</td>
</tr>
</tbody>
</table>

**Counseling.** Counseling delivered by physicians and other health professionals significantly increases quit rates over self-initiated strategies.29 Even brief (3-minute) periods of counseling urging a smoker to quit improve smoking cessation rates.29 There is a relationship between counseling intensity and cessation success.30

VACCINATIONS

Influenza vaccine

Influenza vaccination can reduce serious illness (such as lower respiratory tract infections requiring hospitalization)31 and death in COPD patients.32-35

Pneumococcal vaccine

Pneumococcal vaccinations, PCV13 and PPSV23, are recommended for all patients ≥ 65 years of age (Table 3.2). The PPSV23 is also recommended for younger COPD patients with significant comorbid conditions including chronic heart or lung disease.36 PPSV23 has been shown to reduce the incidence of community-acquired pneumonia in COPD patients < 65 years, with an FEV1 < 40% predicted, or comorbidities (especially cardiac comorbidities).37
Table 3.2. Vaccination for stable COPD

- Influenza vaccination reduces serious illness and death in COPD patients (Evidence B).
- The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been shown to reduce the incidence of community-acquired pneumonia in COPD patients aged < 65 years with an FEV1 < 40% predicted and in those with comorbidities (Evidence B).
- In the general population of adults ≥ 65 years the 13-valent conjugated pneumococcal vaccine (PCV13) has demonstrated significant efficacy in reducing bacteremia and serious invasive pneumococcal disease (Evidence B).

PHARMACOLOGIC THERAPY FOR STABLE COPD

Pharmacologic therapy for COPD is used to reduce symptoms, reduce the frequency and severity of exacerbations, and improve exercise tolerance and health status. To date, there is no conclusive clinical trial evidence that any existing medications for COPD modify the long-term decline in lung function.38-42

The classes of medications commonly used to treat COPD are shown in Table 3.3.

Bronchodilators

Bronchodilators are medications that increase FEV1 and/or change other spirometric variables.

- Bronchodilator medications in COPD are most often given on a regular basis to prevent or reduce symptoms.
- Toxicity is also dose-related (Table 3.3).
- Use of short acting bronchodilators on a regular basis is not generally recommended.

Beta2-agonists

- The principal action of beta2-agonists is to relax airway smooth muscle by stimulating beta2-adrenergic receptors, which increases cyclic AMP and produces functional antagonism to bronchoconstriction.
- There are short-acting (SABA) and long-acting (LABA) beta2-agonists.
- Formoterol and salmeterol are twice-daily LABAs that significantly improve FEV1 and lung volumes, dyspnea, health status, exacerbation rate and number of hospitalizations,43 but have no effect on mortality or rate of decline of lung function.
- Indacaterol is a once daily LABA that improves breathlessness,44,45 health status45 and exacerbation rate.45
- Oladaterol and vilanterol are additional once daily LABAs that improve lung function and symptoms.46,47
- Adverse effects. Stimulation of beta2-adrenergic receptors can produce resting sinus tachycardia and has the potential to precipitate cardiac rhythm disturbances in susceptible patients. Exaggerated somatic tremor is troublesome in some older patients treated with higher doses of beta2-agonists, regardless of route of administration.

Antimuscarinic drugs

- Antimuscarinic drugs block the bronchoconstrictor effects of acetylcholine on M3 muscarinic receptors expressed in airway smooth muscle.48
• Short-acting antimuscarinics (SAMAs), namely ipratropium and oxitropium and long-acting antimuscarinic antagonists (LAMAs), such as tiotropium, aclidinium, glycopyrronium bromide and umeclidinium act on the receptors in different ways.\textsuperscript{48}

• A systematic review of RCTs found that ipratropium alone provided small benefits over short-acting beta\textsubscript{2}-agonist in terms of lung function, health status and requirement for oral steroids.\textsuperscript{49}

• Clinical trials have shown a greater effect on exacerbation rates for LAMA treatment (tiotropium) versus LABA treatment.\textsuperscript{50,51}

• \textbf{Adverse effects}. Inhaled anticholinergic drugs are poorly absorbed which limits the troublesome systemic effects observed with atropine.\textsuperscript{48,52} Extensive use of this class of agents in a wide range of doses and clinical settings has shown them to be very safe. The main side effect is dryness of mouth.\textsuperscript{53,54}

\textbf{Methylxanthines}

• Controversy remains about the exact effects of xanthine derivatives.

• Theophylline, the most commonly used methylxanthine, is metabolized by cytochrome P450 mixed function oxidases. Clearance of the drug declines with age.

• There is evidence for a modest bronchodilator effect compared with placebo in stable COPD.\textsuperscript{55}

• Addition of theophylline to salmeterol produces a greater improvement in FEV\textsubscript{1} and breathlessness than salmeterol alone.\textsuperscript{56,57}

• There is limited and contradictory evidence regarding the effect of low-dose theophylline on exacerbation rates.\textsuperscript{58,59}

• \textbf{Adverse effects}. Toxicity is dose-related, which is a particular problem with xanthine derivatives because their therapeutic ratio is small and most of the benefit occurs only when near-toxic doses are given.\textsuperscript{55-59}

\textbf{Combination bronchodilator therapy}

• Combining bronchodilators with different mechanisms and durations of action may increase the degree of bronchodilation with a lower risk of side-effects compared to increasing the dose of a single bronchodilator.\textsuperscript{61}

• Combinations of SABAs and SAMAs are superior compared to either medication alone in improving FEV\textsubscript{1} and symptoms.\textsuperscript{62}

• Treatment with formoterol and tiotropium in \textit{separate inhalers} has a bigger impact on FEV\textsubscript{1} than either component alone.\textsuperscript{63}

• There are numerous combinations of a LABA and LAMA in a \textit{single inhaler} available (\textbf{Table 3.3}).

• A lower dose, twice daily regimen for a LABA/LAMA has also been shown to improve symptoms and health status in COPD patients (\textbf{Table 3.4}).
### Table 3.3. Commonly used maintenance medications in COPD*

<table>
<thead>
<tr>
<th>Drug</th>
<th>Inhaler (mcg)</th>
<th>Solution for nebulizer (mg/ml)</th>
<th>Oral</th>
<th>Vials for injection (mg)</th>
<th>Duration of action (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Beta,-agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Short-acting</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenoterol</td>
<td>100-200 (MDI)</td>
<td>1</td>
<td>2.5 mg (pill), 0.05% (syrup)</td>
<td>4-6</td>
<td></td>
</tr>
<tr>
<td>Levalbuterol</td>
<td>45-90 (MDI)</td>
<td>0.1, 0.21, 0.25, 0.42</td>
<td>2, 4, 5 mg (pill), 8 mg (extended release tablet) 0.024%/0.4 mg (syrup)</td>
<td>6-8</td>
<td></td>
</tr>
<tr>
<td>Salbutamol (albuterol)</td>
<td>90, 100, 200 (MDI &amp; DPI)*</td>
<td>1, 2, 2.5, 5 mg/ml</td>
<td>0.1, 0.5 mg</td>
<td>4-6, 12 (extended release)</td>
<td></td>
</tr>
<tr>
<td>Terbutaline</td>
<td>500 (DPI)</td>
<td>2.5, 5 mg (pill)</td>
<td>0.2, 0.25, 1 mg</td>
<td>4-6</td>
<td></td>
</tr>
<tr>
<td><strong>Long-acting</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arformoterol</td>
<td></td>
<td>0.0075†</td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Formoterol</td>
<td>4.5-9 (DPI)</td>
<td>0.01 ‡</td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Indacaterol</td>
<td>75-300 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Olodaterol</td>
<td>2.5, 5 (SMI)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>25-50 (MDI &amp; DPI)</td>
<td>1 mg (solution)</td>
<td>0.2 mg</td>
<td>12-24</td>
<td></td>
</tr>
<tr>
<td><strong>Anticholinergics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Short-acting</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipratropium bromide</td>
<td>20, 40 (MDI)</td>
<td>0.2</td>
<td></td>
<td></td>
<td>6-8</td>
</tr>
<tr>
<td>Oxitropium bromide</td>
<td>100 (MDI)</td>
<td></td>
<td></td>
<td></td>
<td>7-8</td>
</tr>
<tr>
<td><strong>Long-acting</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acclidinium bromide</td>
<td>400 (DPI), 400 (MDI)</td>
<td>1 mg (solution)</td>
<td>0.2 mg</td>
<td>12-24</td>
<td></td>
</tr>
<tr>
<td>Glycopyronium bromide</td>
<td>15.6 &amp; 50 (DPI)*</td>
<td>1 mg (solution)</td>
<td>0.2 mg</td>
<td>12-24</td>
<td></td>
</tr>
<tr>
<td>Tiotropium</td>
<td>18 (DPI), 2.5 &amp; 5 (SMI)</td>
<td>1 mg (solution)</td>
<td>0.2 mg</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Umecldinium</td>
<td>62.5 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td><strong>Combination of short-acting beta,-agonist plus anticholinergic in one device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenoterol/ipratropium</td>
<td>50/20 (SMI)</td>
<td>1.25, 0.5 mg in 4ml</td>
<td></td>
<td></td>
<td>6-8</td>
</tr>
<tr>
<td>Salbutamol/ipratropium</td>
<td>100/20 (SMI), 75/15 (MDI)</td>
<td>0.5, 2.5 mg in 3ml</td>
<td>6-8</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Combination of long-acting beta,-agonist plus anticholinergic in one device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/acclidinium</td>
<td>12/400 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Formoterol/glycopyronium</td>
<td>9.6/14.4 (MDI)</td>
<td></td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Indacaterol/glycopyronium</td>
<td>27.5/15.6 &amp; 110/60 (DPI)*</td>
<td></td>
<td></td>
<td></td>
<td>12-24</td>
</tr>
<tr>
<td>Vilanterol/umecldinium</td>
<td>25/62.5 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Olodaterol/tiotropium</td>
<td>5/5 (SMI)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td><strong>Methylxanthines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aminophylline</td>
<td></td>
<td>105 mg/ml (solution)</td>
<td>250, 500 mg</td>
<td>Variable, up to 24</td>
<td></td>
</tr>
<tr>
<td>Theophylline (SR)</td>
<td></td>
<td>100-600 mg (pill)</td>
<td>250, 400, 500 mg</td>
<td>Variable, up to 24</td>
<td></td>
</tr>
<tr>
<td><strong>Combination of long-acting beta,-agonist plus corticosteroids in one device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/beclohexethasone</td>
<td>6/100 (MDI &amp; DPI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/budesonide</td>
<td>4.5/160 (MDI), 4.5/80 (MDI), 9/320 (DPI), 9/160 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/mometasone</td>
<td>10/200, 10/400 (MDI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salmeterol/fluticasone</td>
<td>5/100, 5/250, 5/500 (DPI), 21/45, 21/115, 21/230 (MDI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vilanterol/fluticasone</td>
<td>25/100 (DPI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Phosphodiesterase-4 inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotflurastil</td>
<td>500 mcg (pill)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MDI = metered dose inhaler; DPI = dry powder inhaler; SMI = soft mist inhaler

* Not all formulations are available in all countries; in some countries other formulations and dosages may be available

† Dose availability varies by country

‡ Formoterol nebulized solution is based on the unit dose vial containing 20 mcg in a volume of 2.0 ml

§ Dose varies by country


**Table 3.4. Bronchodilators in stable COPD**

- Inhaled bronchodilators in COPD are central to symptom management and commonly given on a regular basis to prevent or reduce symptoms (Evidence A).
- Regular and as-needed use of SABA or SAMA improves FEV₁ and symptoms (Evidence A).
- Combinations of SABA and SAMA are superior compared to either medication alone in improving FEV₁ and symptoms (Evidence A).
- LABAs and LAMAs significantly improve lung function, dyspnea, health status, and reduce exacerbation rates (Evidence A).
- LAMAs have a greater effect on exacerbation reduction compared with LABAs (Evidence A) and decrease hospitalizations (Evidence B).
- Combination treatment with a LABA and LAMA increases FEV₁ and reduces symptoms compared to monotherapy (Evidence A).
- Combination treatment with a LABA and LAMA reduces exacerbations compared to monotherapy (Evidence B) or ICS/LABA (Evidence B).
- Tiotropium improves the effectiveness of pulmonary rehabilitation in increasing exercise performance (Evidence B).
- Theophylline exerts a small bronchodilator effect in stable COPD (Evidence A) and that is associated with modest symptomatic benefits (Evidence B).

### Anti-inflammatory agents

- To date, exacerbations (e.g., exacerbation rate, patients with at least one exacerbation, time-to-first exacerbation) represent the main clinically relevant end-point used for efficacy assessment of drugs with anti-inflammatory effects (Table 3.5).

### Inhaled corticosteroids (ICS)

- **ICS in combination with long-acting bronchodilator therapy.** In patients with moderate to very severe COPD and exacerbations, an ICS combined with a LABA is more effective than either component alone in improving lung function, health status and reducing exacerbations.65,66
- **Adverse effects.** There is high quality evidence from randomized controlled trials (RCTs) that ICS use is associated with higher prevalence of oral candidiasis, hoarse voice, skin bruising and pneumonia.67
- **Withdrawal of ICS.** Results from withdrawal studies provide equivocal results regarding consequences of withdrawal on lung function, symptoms and exacerbations.68-72 Differences between studies may relate to differences in methodology, including the use of background long-acting bronchodilator medication(s) which may minimize any effect of ICS withdrawal.
• Triple inhaled therapy
  o The step up in inhaled treatment to LABA plus LAMA plus ICS (triple therapy) can occur by various approaches. 72
  o This may improve lung function and patient reported outcomes. 74-77
  o Adding a LAMA to existing LABA/ICS improves lung function and patient reported outcomes, in particular exacerbation risk. 75, 78-80
  o A RCT did not demonstrate any benefit of adding ICS to LABA plus LAMA on exacerbations. 81
  o Altogether, more evidence is needed to draw conclusions on the benefits of triple therapy LABA/LAMA/ICS compared to LABA/LAMA.

• Oral glucocorticoids
  o Oral glucocorticoids have numerous side effects, including steroid myopathy 82 which can contribute to muscle weakness, decreased functionality, and respiratory failure in subjects with very severe COPD.
  o While oral glucocorticoids play a role in the acute management of exacerbations, they have no role in the chronic daily treatment in COPD because of a lack of benefit balanced against a high rate of systemic complications.

• Phosphodiesterase-4 (PDE4) inhibitors
  o Roflumilast reduces moderate and severe exacerbations treated with systemic corticosteroids in patients with chronic bronchitis, severe to very severe COPD, and a history of exacerbations. 83
  o Adverse effects. PDE4 inhibitors have more adverse effects than inhaled
medications for COPD. The most frequent are nausea, reduced appetite, weight loss, abdominal pain, diarrhea, sleep disturbance, and headache.

- Antibiotics
  - More recent studies have shown that regular use of macrolide antibiotics may reduce exacerbation rate.

- Mucolytic (mucokinetics, mucoregulators) and antioxidant agents (NAC, carbocysteine)
  - In COPD patients not receiving inhaled corticosteroids, regular treatment with mucolytics such as carbocysteine and N-acetylcysteine may reduce exacerbations and modestly improve health status.

Issues related to inhaled delivery

- Determinants of poor inhaler technique in asthma and COPD patients include: older age, use of multiple devices, and lack of previous education on inhaler technique.
- The main errors in delivery device use relate to problems with inhalation rate, inhalation duration, coordination, dose preparation, exhalation maneuver prior to inhalation and breath-holding following dose inhalation (Table 3.6).

<table>
<thead>
<tr>
<th>Table 3.6. The inhaled route</th>
</tr>
</thead>
<tbody>
<tr>
<td>- When a treatment is given by the inhaled route, the importance of education and training in inhaler device technique cannot be over-emphasized.</td>
</tr>
<tr>
<td>- The choice of inhaler device has to be individually tailored and will depend on access, cost, prescriber, and most importantly, patient’s ability and preference.</td>
</tr>
<tr>
<td>- It is essential to provide instructions and to demonstrate the proper inhalation technique when prescribing a device, to ensure that inhaler technique is adequate and re-check at each visit that patients continue to use their inhaler correctly.</td>
</tr>
<tr>
<td>- Inhaler technique (and adherence to therapy) should be assessed before concluding that the current therapy is insufficient.</td>
</tr>
</tbody>
</table>

Other pharmacologic treatments

Other pharmacologic treatments for COPD are summarized in Table 3.7.

<table>
<thead>
<tr>
<th>Table 3.7. Other pharmacological treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-1 antitrypsin augmentation therapy</td>
</tr>
<tr>
<td>- Intravenous augmentation therapy may slow down the progression of emphysema (Evidence B).</td>
</tr>
<tr>
<td>Antitussives</td>
</tr>
<tr>
<td>- There is no conclusive evidence of a beneficial role of antitussives in patients with COPD (Evidence C).</td>
</tr>
<tr>
<td>Vasodilators</td>
</tr>
<tr>
<td>- Vasodilators do not improve outcomes and may worsen oxygenation (Evidence B).</td>
</tr>
</tbody>
</table>
REHABILITATION, EDUCATION & SELF-MANAGEMENT

Pulmonary rehabilitation

- The benefits to COPD patients from pulmonary rehabilitation are considerable (Table 3.8), and rehabilitation has been shown to be the most effective therapeutic strategy to improve shortness of breath, health status and exercise tolerance.91

<table>
<thead>
<tr>
<th>Table 3.8. Pulmonary rehabilitation, self-management and integrative care in COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary rehabilitation</td>
</tr>
<tr>
<td>- Pulmonary rehabilitation</td>
</tr>
<tr>
<td>improves dyspnea, health status</td>
</tr>
<tr>
<td>and exercise tolerance in stable patients (Evidence A).</td>
</tr>
<tr>
<td>- Pulmonary rehabilitation</td>
</tr>
<tr>
<td>reduces hospitalizations</td>
</tr>
<tr>
<td>among patients who have had</td>
</tr>
<tr>
<td>a recent exacerbation (≤ 4 weeks from prior hospitalization) (Evidence B).</td>
</tr>
<tr>
<td>Education and self-management</td>
</tr>
<tr>
<td>- Education alone has not been</td>
</tr>
<tr>
<td>shown to be effective (Evidence C).</td>
</tr>
<tr>
<td>- Self-management intervention</td>
</tr>
<tr>
<td>with communication with a</td>
</tr>
<tr>
<td>health care professional</td>
</tr>
<tr>
<td>improves health status and</td>
</tr>
<tr>
<td>decreases hospitalizations</td>
</tr>
<tr>
<td>and emergency department</td>
</tr>
<tr>
<td>visits (Evidence B).</td>
</tr>
<tr>
<td>Integrated care programs</td>
</tr>
<tr>
<td>- Integrated care and telehealth</td>
</tr>
<tr>
<td>have no demonstrated benefit</td>
</tr>
<tr>
<td>at this time (Evidence B).</td>
</tr>
</tbody>
</table>

SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE

Symptom control and palliative care

- COPD is a highly symptomatic disease and has many elements such as fatigue, dyspnea, depression, anxiety, insomnia that require symptom-based palliative treatments.
- Palliative approaches are essential in the context of end-of-life care as well as hospice care (a model for delivery of end-of-life care for patients who are terminally ill and predicted to have less than 6 months to live).

Key points for palliative, end-of-life and hospice care in COPD are summarized in Table 3.9.

<table>
<thead>
<tr>
<th>Table 3.9. Palliative care, end of life and hospice care in COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Opiates, neuromuscular electrical stimulation (NMES), oxygen and fans blowing air onto the face can relieve breathlessness (Evidence C).</td>
</tr>
<tr>
<td>- In malnourished patients, nutritional supplementation may improve respiratory muscle strength and overall health status (Evidence B).</td>
</tr>
<tr>
<td>- Fatigue can be improved by self-management education, pulmonary rehabilitation, nutritional support and mind-body interventions (Evidence B).</td>
</tr>
</tbody>
</table>
OTHER TREATMENTS

Oxygen therapy and ventilatory support

**Oxygen therapy.**
- The long-term administration of oxygen (> 15 hours per day) to patients with chronic respiratory failure has been shown to increase survival in patients with severe resting hypoxemia (Table 3.10).

**Ventilatory support**
- Noninvasive ventilation (NIV) in the form of noninvasive positive pressure ventilation (NPPV) is the standard of care for decreasing morbidity and mortality in patients hospitalized with an exacerbation of COPD and acute respiratory failure.

**Stable patient**
- NPPV may improve hospitalization-free survival in selected patients after recent hospitalization, particularly in those with pronounced daytime persistent hypercapnia (PaCO₂ ≥ 52 mmHg).

**Interventional Treatments**
- The advantage of lung volume reduction surgery (LVRS) over medical therapy is more significant among patients with upper-lobe predominant emphysema and low exercise capacity after rehabilitation; although LVRS is costly relative to health-care programs not including surgery.
- Non-surgical bronchoscopic lung volume reduction techniques may improve exercise tolerance, health status and lung function in selected patients with advanced emphysema refractory to medical therapy.
- In appropriately selected patients with very severe COPD, lung transplantation has been shown to improve quality of life and functional capacity.
• Key points for interventional therapy in stable COPD are summarized in Table 3.11, and an algorithm depicting an overview of various interventions is shown in Figure 4.3.

<table>
<thead>
<tr>
<th>Table 3.11. Interventional therapy in stable COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lung volume reduction surgery</strong></td>
</tr>
<tr>
<td>• Lung volume reduction surgery improves survival in severe emphysema patients with an upper- lobe emphysema and low post--rehabilitation exercise capacity (Evidence A).</td>
</tr>
<tr>
<td><strong>Bullectomy</strong></td>
</tr>
<tr>
<td>• In selected patients bullectomy is associated with decreased dyspnea, improved lung function and exercise tolerance (Evidence C).</td>
</tr>
<tr>
<td><strong>Transplantation</strong></td>
</tr>
<tr>
<td>• In appropriately selected patients with very severe COPD, lung transplantation has been shown to improve quality of life and functional capacity (Evidence C).</td>
</tr>
<tr>
<td><strong>Bronchoscopic interventions</strong></td>
</tr>
<tr>
<td>• In select patients with advanced emphysema, bronchoscopic interventions reduces end--expiratory lung volume and improves exercise tolerance, health status and lung function at 6-12 months following treatment. Endobronchial valves (Evidence B); Lung coils (Evidence B).</td>
</tr>
</tbody>
</table>

**Figure 4.3. Interventional Bronchoscopic and Surgical Treatments for COPD**

Overview of various therapies used to treat patients with COPD and emphysema worldwide. Note that all therapies are not approved for clinical care in all countries. Additionally, the effects of BLVR on survival or other long term outcomes or comparison to LVRS are unknown.

Definition of Abbreviations: BLVR: Bronchoscopic Lung Volume Reduction, EBV: endobronchial Valve, LVRS: Lung volume reduction surgery, LVRC: Lung volume reduction coil

*at some but not all centers
MANAGEMENT OF STABLE COPD

OVERALL KEY POINTS:

- The management strategy for stable COPD should be predominantly based on the individualized assessment of symptoms and future risk of exacerbations.
- All individuals who smoke should be strongly encouraged and supported to quit.
- The main treatment goals are reduction of symptoms and future risk of exacerbations.
- Management strategies are not limited to pharmacological treatments, and should be complemented by appropriate non-pharmacological interventions.

Once COPD has been diagnosed, effective management should be based on an individualized assessment to reduce both current symptoms and future risks of exacerbations (Table 4.1).

<table>
<thead>
<tr>
<th>Table 4.1. Goals for treatment of stable COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Relieve symptoms</td>
</tr>
<tr>
<td>• Improve exercise tolerance</td>
</tr>
<tr>
<td>• Improve health status</td>
</tr>
</tbody>
</table>

and

| • Prevent disease progression |
| • Prevent and treat exacerbations |
| • Reduce mortality |

REDUCE SYMPTOMS

REDUCE RISK

IDENTIFY AND REDUCE EXPOSURE TO RISK FACTORS

Identification and reduction of exposure to risk factors (Table 4.2 and 4.3) is important in the treatment and prevention of COPD. Cigarette smoking is the most commonly encountered and easily identifiable risk factor for COPD, and smoking cessation should be continually encouraged for all individuals who smoke. Reduction of total personal exposure to occupational dusts, fumes, and gases, and to indoor and outdoor air pollutants, should also be addressed.
TREATMENT OF STABLE COPD

PHARMACOLOGIC TREATMENT

Pharmacologic therapies can reduce symptoms, and the risk and severity of exacerbations, as well as improve health status and exercise tolerance.

Most of the drugs are inhaled so proper inhaler technique is of high relevance. Key points for the inhalation of drugs are given in Table 4.4. Key points for bronchodilator use are given in Table 4.5. Key points for the use of anti-inflammatory agents are summarized in Table 4.6. Key points for the use of other pharmacologic treatments are summarized in Table 4.7.

**Table 4.2. Treating tobacco use and dependence: A clinical practice guideline – major findings and recommendations.**

- Tobacco dependence is a chronic condition that warrants repeated treatment until long-term or permanent abstinence is achieved.
- Effective treatments for tobacco dependence exist and all tobacco users should be offered these treatments.
- Clinicians and health care delivery systems must operationalize the consistent identification, documentation, and treatment of every tobacco user at every visit.
- Brief smoking cessation counseling is effective and every tobacco user should be offered such advice at every contact with health care providers.
- There is a strong dose-response relation between the intensity of tobacco dependence counseling and its effectiveness.
- Three types of counseling have been found to be especially effective: practical counseling, social support of family and friends as part of treatment, and social support arranged outside of treatment.
- First-line pharmacotherapies for tobacco dependence—varenicline, bupropion sustained release, nicotine gum, nicotine inhaler, nicotine nasal spray, and nicotine patch—are effective and at least one of these medications should be prescribed in the absence of contraindications.
- Financial incentive programs for smoking cessation may facilitate smoking cessation.
- Tobacco dependence treatments are cost effective interventions.

**Table 4.3. Identify and reduce risk factor exposure**

- Smoking cessation interventions should be actively pursued in all COPD patients (Evidence A).
- Efficient ventilation, non-polluting cooking stoves and similar interventions should be recommended (Evidence B).
- Clinicians should advise patients to avoid continued exposures to potential irritants, if possible (Evidence D).

<table>
<thead>
<tr>
<th>Table 4.4. Key points for inhalation of drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>- The choice of inhaler device has to be individually tailored and will depend on access, cost, prescriber, and most importantly, patient’s ability and preference.</td>
</tr>
<tr>
<td>- It is essential to provide instructions and to demonstrate the proper inhalation technique when prescribing a device, to ensure that inhaler technique is adequate and re-check at each visit that patients continue to use their inhaler correctly.</td>
</tr>
<tr>
<td>- Inhaler technique (and adherence to therapy) should be assessed before concluding that the current therapy requires modification.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 4.5. Key points for the use of bronchodilators</th>
</tr>
</thead>
<tbody>
<tr>
<td>- LABAs and LAMAs are preferred over short-acting agents except for patients with only occasional dyspnea. (Evidence A).</td>
</tr>
<tr>
<td>- Patients may be started on single long-acting bronchodilator therapy or dual long-acting bronchodilator therapy. In patients with persistent dyspnea on one bronchodilator treatment should be escalated to two (Evidence A).</td>
</tr>
<tr>
<td>- Inhaled bronchodilators are recommended over oral bronchodilators (Evidence A).</td>
</tr>
<tr>
<td>- Theophylline is not recommended unless other long-term treatment bronchodilators are unavailable or unaffordable (Evidence B).</td>
</tr>
</tbody>
</table>
**Table 4.6. Key points for the use of anti-inflammatory agents**

- Long-term monotherapy with ICS is not recommended (Evidence A).
- Long-term treatment with ICS may be considered in association with LABAs for patients with a history of exacerbations despite appropriate treatment with long-acting bronchodilators (Evidence A).
- Long-term therapy with oral corticosteroids is not recommended (Evidence A).
- In patients with exacerbations despite LABA/ICS or LABA/LAMA/ICS, chronic bronchitis and severe to very severe airflow obstruction, the addition of a PDE4 inhibitor can be considered (Evidence B).
- In former smokers with exacerbations despite appropriate therapy, macrolides can be considered (Evidence B).
- Statin therapy is not recommended for prevention of exacerbations (Evidence A).
- Antioxidant mucolytics are recommended only in selected patients (Evidence A).

**Table 4.7. Key points for the use of other pharmacological treatments**

- Patients with severe hereditary alpha-1 antitrypsin deficiency and established emphysema may be candidates for alpha-1 antitrypsin augmentation therapy (Evidence B).
- Antitussives cannot be recommended (Evidence C).
- Drugs approved for primary pulmonary hypertension are not recommended for patients with a pulmonary hypertension secondary to COPD (Evidence B).
- Low-dose long acting oral and parenteral opioids may be considered for treating dyspnea in COPD patients with severe disease (Evidence B).
Pharmacologic treatment algorithms

A proposed model for the initiation, and then subsequent escalation and/or de-escalation of pharmacologic management of COPD according to the individualized assessment of symptoms and exacerbation risk is shown in Figure 4.1.

In past versions of the GOLD Report, recommendations were only given for initial therapy. However, many COPD patients are already on treatment and return with persistent symptoms after initial therapy, or less commonly with resolution of some symptoms that subsequently may require less therapy. Therefore, we now suggest escalation (and de-escalation) strategies. The recommendations made are based on available efficacy as well as safety data. We are fully aware that treatment escalation has not been systematically tested; trials of de-escalation are also limited and only include ICS.

These recommendations will be re-evaluated as additional data become available.

Figure 4.1. Pharmacologic treatment algorithms by GOLD Grade [highlighted boxes and arrows indicate preferred treatment pathways]
Some relevant non-pharmacologic measures for patient groups A to D are summarized in Table 4.8. An appropriate algorithm for the prescription of oxygen to patients with COPD is shown in Figure 4.2.
Key points for the use of non-pharmacological treatments are given in Table 4.9.

<table>
<thead>
<tr>
<th>Table 4.9. Key points for the use of non-pharmacological treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Education, self-management and pulmonary rehabilitation</strong></td>
</tr>
<tr>
<td>• Education is needed to change patient’s knowledge but there is no evidence that used alone will change patient behavior.</td>
</tr>
<tr>
<td>• Education self-management with the support of a case manager with or without the use of a written action plan is recommended for the prevention of exacerbation complications such as hospital admissions (Evidence B).</td>
</tr>
<tr>
<td>• Rehabilitation is indicated in all patients with relevant symptoms and/or a high risk for exacerbation (Evidence A).</td>
</tr>
<tr>
<td>• Physical activity is a strong predictor of mortality (Evidence A). Patients should be encouraged to increase the level of physical activity although we still don’t know how to best insure the likelihood of success.</td>
</tr>
<tr>
<td><strong>Vaccination</strong></td>
</tr>
<tr>
<td>• Influenza vaccination is recommended for all patients with COPD (Evidence A).</td>
</tr>
<tr>
<td>• Pneumococcal vaccination: the PCV13 and PPSV23 are recommended for all patients &gt; 65 years of age, and in younger patients with significant comorbid conditions including chronic heart or lung disease (Evidence B).</td>
</tr>
<tr>
<td><strong>Nutrition</strong></td>
</tr>
<tr>
<td>• Nutritional supplementation should be considered in malnourished patients with COPD (Evidence B).</td>
</tr>
<tr>
<td><strong>End of life and palliative care</strong></td>
</tr>
<tr>
<td>• All clinicians managing patients with COPD should be aware of the effectiveness of palliative approaches to symptom control and use these in their practice (Evidence D).</td>
</tr>
<tr>
<td>• End of life care should include discussions with patients and their families about their views on resuscitation, advance directives and place of death preferences (Evidence D).</td>
</tr>
<tr>
<td><strong>Treatment of hypoxemia</strong></td>
</tr>
<tr>
<td>• In patients with severe resting hypoxemia long-term oxygen therapy is indicated (Evidence A).</td>
</tr>
<tr>
<td>• In patients with stable COPD and resting or exercise-induced moderate desaturation, long term oxygen treatment should not be routinely prescribed. However, individual patient factors may be considered when evaluating the patient’s needs for supplemental oxygen (Evidence A).</td>
</tr>
<tr>
<td>• Resting oxygenation at sea level does not exclude the development of severe hypoxemia when travelling by air (Evidence C).</td>
</tr>
<tr>
<td><strong>Treatment of hypercapnia</strong></td>
</tr>
<tr>
<td>• In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, long term non-invasive ventilation may be considered (Evidence B).</td>
</tr>
<tr>
<td><strong>Intervention bronchoscopy and surgery</strong></td>
</tr>
<tr>
<td>• Lung volume reduction surgery should be considered in selected patients with upper-lobe emphysema (Evidence A).</td>
</tr>
<tr>
<td>• Bronchoscopic lung volume reduction interventions may be considered in selected patients with advanced emphysema (Evidence B).</td>
</tr>
<tr>
<td>• In selected patients with a large bulla surgical bullectomy may be considered (Evidence C).</td>
</tr>
<tr>
<td>• In patients with very severe COPD (progressive disease, BODE score of 7 to 10, and not candidate for lung volume reduction) lung transplantation may be considered for referral with at least one of the following: (1) history of hospitalization for exacerbation associated with acute hypercapnia (P&lt;sub&gt;co2&lt;/sub&gt; &gt; 50 mm Hg); (2) pulmonary hypertension and/or cor pulmonale, despite oxygen therapy; or (3) FEV&lt;sub&gt;1&lt;/sub&gt; &lt; 20% and either DLCO &lt; 20% or homogenous distribution of emphysema (Evidence C).</td>
</tr>
</tbody>
</table>

**MONITORING AND FOLLOW-UP**

Routine follow-up of COPD patients is essential. Lung function may worsen over time, even with the best available care. Symptoms, exacerbations and objective measures of airflow limitation should be monitored to determine when to modify management and to identify any complications and/or comorbidities that may develop. Based on current literature, comprehensive self-management or routine monitoring has not shown long term benefits in terms of health status over usual care alone for COPD patients in general practice.\(^{100}\)
MANAGEMENT OF EXACERBATIONS

OVERALL KEY POINTS:

- An exacerbation of COPD is defined as an acute worsening of respiratory symptoms that results in additional therapy.
- Exacerbations of COPD can be precipitated by several factors. The most common causes are respiratory tract infections.
- The goal for treatment of COPD exacerbations is to minimize the negative impact of the current exacerbation and to prevent subsequent events.
- Short-acting inhaled beta₂-agonists, with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation.
- Maintenance therapy with long-acting bronchodilators should be initiated as soon as possible before hospital discharge.
- Systemic corticosteroids can improve lung function (FEV₁), oxygenation and shorten recovery time and hospitalization duration. Duration of therapy should not be more than 5-7 days.
- Antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse, treatment failure, and hospitalization duration. Duration of therapy should be 5-7 days.
- Methylxanthines are not recommended due to increased side effect profiles.
- Non-invasive mechanical ventilation should be the first mode of ventilation used in COPD patients with acute respiratory failure who have no absolute contraindication because it improves gas exchange, reduces work of breathing and the need for intubation, decreases hospitalization duration and improves survival.
- Following an exacerbation, appropriate measures for exacerbation prevention should be initiated (see Chapters 3 and 4 of GOLD 2017 full report).

COPD exacerbations are defined as an acute worsening of respiratory symptoms that result in additional therapy.¹⁰¹,¹⁰²

They are classified as:

- Mild (treated with short acting bronchodilators only, SABDs)
- Moderate (treated with SABDs plus antibiotics and/or oral corticosteroids) or
- Severe (patient requires hospitalization or visits the emergency room). Severe exacerbations may also be associated with acute respiratory failure.
Exacerbations of COPD are important events in the management of COPD because they negatively impact health status, rates of hospitalization and readmission, and disease progression. COPD exacerbations are complex events usually associated with increased airway inflammation, increased mucous production and marked gas trapping. These changes contribute to increased dyspnea that is the key symptom of an exacerbation. Other symptoms include increased sputum purulence and volume, together with increased cough and wheeze. As co-morbidities are common in COPD patients, exacerbations must be differentiated clinically from other events such as acute coronary syndrome, worsening congestive heart failure, pulmonary embolism and pneumonia.

## TREATMENT OPTIONS

### Treatment Setting

The goals of treatment for COPD exacerbations are to minimize the negative impact of the current exacerbation and prevent the development of subsequent events. Depending on the severity of an exacerbation and/or the severity of the underlying disease, an exacerbation can be managed in either the outpatient or inpatient setting. More than 80% of exacerbations are managed on an outpatient basis with pharmacologic therapies including bronchodilators, corticosteroids, and antibiotics.

The clinical presentation of COPD exacerbation is heterogeneous, thus we recommend that in hospitalized patients the severity of the exacerbation should be based on the patient’s clinical signs and recommend the following classification.

**No respiratory failure:** Respiratory rate: 20-30 breaths per minute; no use of accessory respiratory muscles; no changes in mental status; hypoxemia improved with supplemental oxygen given via Venturi mask 28-35% inspired oxygen (FiO₂); no increase in PaCO₂.

**Acute respiratory failure — non-life-threatening:** Respiratory rate: > 30 breaths per minute; using accessory respiratory muscles; no change in mental status; hypoxemia improved with supplemental oxygen via Venturi mask 25-30% FiO₂; hypercarbia i.e., PaCO₂ increased compared with baseline or elevated 50-60 mmHg.

**Acute respiratory failure — life-threatening:** Respiratory rate: > 30 breaths per minute; using accessory respiratory muscles; acute changes in mental status; hypoxemia not improved with supplemental oxygen via Venturi mask or requiring FiO₂ > 40%; hypercarbia i.e., PaCO₂ increased compared with baseline or elevated > 60 mmHg or the presence of acidosis (pH < 7.25).
The indications for assessing the need for hospitalization during a COPD exacerbation are shown in Table 5.1. When patients with a COPD exacerbation come to the emergency department, they should be provided with supplemental oxygen and undergo assessment to determine whether the exacerbation is life-threatening and if increased work of breathing or impaired gas exchange requires consideration for non-invasive ventilation. The management of severe, but not life threatening, exacerbations is outlined in Table 5.2.

Key points for the management of exacerbations are given in Table 5.3.
Pharmacologic Treatment

The three classes of medications most commonly used for COPD exacerbations are bronchodilators, corticosteroids, and antibiotics.

Respiratory Support

Oxygen therapy

- This is a key component of hospital treatment of an exacerbation. Supplemental oxygen should be titrated to improve the patient’s hypoxemia with a target saturation of 88-92%. 106
- Once oxygen is started, blood gases should be checked frequently to ensure satisfactory oxygenation without carbon dioxide retention and/or worsening acidosis.

Ventilatory Support

- Some patients need immediate admission to the respiratory care or intensive care unit (ICU) (Table 5.4).
- Ventilatory support in an exacerbation can be provided by either noninvasive (nasal or facial mask) or invasive (oro-tracheal tube or tracheostomy) ventilation.
- Respiratory stimulants are not recommended for acute respiratory failure. 107

<table>
<thead>
<tr>
<th>Table 5.4. Indications for respiratory or medical intensive care unit admission*</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Severe dyspnea that responds inadequately to initial emergency therapy.</td>
</tr>
<tr>
<td>• Changes in mental status (confusion, lethargy, coma).</td>
</tr>
<tr>
<td>• Persistent or worsening hypoxemia (PaO2 &lt; 5.3 kPa or 40 mmHg) and/or severe/worsening respiratory acidosis (pH &lt; 7.25) despite supplemental oxygen and noninvasive ventilation.</td>
</tr>
<tr>
<td>• Need for invasive mechanical ventilation.</td>
</tr>
<tr>
<td>• Hemodynamic instability—need for vasopressors.</td>
</tr>
</tbody>
</table>

*Local resources need to be considered.

Noninvasive mechanical ventilation

- The use of noninvasive mechanical ventilation (NIV) is preferred over invasive ventilation (intubation and positive pressure ventilation) as the initial mode of ventilation to treat acute respiratory failure in patients hospitalized for acute exacerbations of COPD.
- The indications for NIV 108 are summarized in Table 5.5.

<table>
<thead>
<tr>
<th>Table 5.5. Indications for noninvasive mechanical ventilation (NIV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least one of the following:</td>
</tr>
<tr>
<td>• Respiratory acidosis (PaCO2 ≥ 6.0 kPa or 45 mmHg and arterial pH ≤ 7.35).</td>
</tr>
<tr>
<td>• Severe dyspnea with clinical signs suggestive of respiratory muscle fatigue, increased work of breathing, or both, such as use of respiratory accessory muscles, paradoxical motion of the abdomen, or retraction of the intercostal spaces.</td>
</tr>
<tr>
<td>• Persistent hypoxemia despite supplemental oxygen therapy.</td>
</tr>
</tbody>
</table>
Invasive mechanical ventilation. The indications for initiating invasive mechanical ventilation during an exacerbation are shown in Table 5.6, and include failure of an initial trial of NIV. Prevention of exacerbations

HOSPITAL DISCHARGE AND FOLLOW-UP

Early follow-up (within one month) following discharge should be undertaken when possible and has been related to less exacerbation-related readmissions. A review of discharge criteria and recommendations for follow-up are summarized in Table 5.7.

Table 5.6. Indications for invasive mechanical ventilation

- Unable to tolerate NIV or NIV failure.
- Status post- respiratory or cardiac arrest.
- Diminished consciousness, psychomotor agitation inadequately controlled by sedation.
- Massive aspiration or persistent vomiting.
- Persistent inability to remove respiratory secretions.
- Severe hemodynamic instability without response to fluids and vasoactive drugs.
- Severe ventricular or supraventricular arrhythmias.
- Life-threatening hypoxemia in patients unable to tolerate NIV.

Table 5.7. Discharge criteria and recommendations for follow-up

- Full review of all clinical and laboratory data.
- Check maintenance therapy and understanding.
- Reassess inhaler technique.
- Ensure understanding of withdrawal of acute medications (steroids and/or antibiotics).
- Assess need for continuing any oxygen therapy.
- Provide management plan for comorbidities and follow-up.
- Ensure follow-up arrangements: early follow-up < 4 weeks, and late follow-up < 12 weeks as indicated.
- All clinical or investigational abnormalities have been identified.

<table>
<thead>
<tr>
<th>1–4 Weeks Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluate ability to cope in his/her usual environment.</td>
</tr>
<tr>
<td>Review and understanding treatment regimen.</td>
</tr>
<tr>
<td>Reassessment of inhaler techniques.</td>
</tr>
<tr>
<td>Reassess need for long-term oxygen.</td>
</tr>
<tr>
<td>Document the capability to do physical activity and activities of daily living.</td>
</tr>
<tr>
<td>Document symptoms; CAT or mMRC.</td>
</tr>
<tr>
<td>Determine status of comorbidities.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12–16 Weeks Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluate ability to cope in his/her usual environment.</td>
</tr>
<tr>
<td>Review understanding treatment regimen.</td>
</tr>
<tr>
<td>Reassessment of inhaler techniques.</td>
</tr>
<tr>
<td>Reassess need for long-term oxygen.</td>
</tr>
<tr>
<td>Document the capacity to do physical activity and activities of daily living.</td>
</tr>
<tr>
<td>Measure spirometry: FEV₁.</td>
</tr>
<tr>
<td>Document symptoms; CAT or mMRC.</td>
</tr>
<tr>
<td>Determine status of comorbidities.</td>
</tr>
</tbody>
</table>
After an acute exacerbation appropriate measures for prevention of further exacerbations should be initiated (Table 5.8).

<table>
<thead>
<tr>
<th>Intervention class</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchodilators</td>
<td>LABAs</td>
</tr>
<tr>
<td></td>
<td>LAMAs</td>
</tr>
<tr>
<td></td>
<td>LABA + LAMA</td>
</tr>
<tr>
<td>Corticosteroid-containing regimens</td>
<td>LABA + ICS</td>
</tr>
<tr>
<td></td>
<td>LABA + LAMA + ICS</td>
</tr>
<tr>
<td>Anti-inflamatory (non-steroid)</td>
<td>Roflumilast</td>
</tr>
<tr>
<td>Anti-infectives</td>
<td>Vaccines</td>
</tr>
<tr>
<td></td>
<td>Long term macrolides</td>
</tr>
<tr>
<td>Mucoregulators</td>
<td>N-acetylcysteine</td>
</tr>
<tr>
<td></td>
<td>Carbocysteine</td>
</tr>
<tr>
<td>Various others</td>
<td>Smoking cessation</td>
</tr>
<tr>
<td></td>
<td>Rehabilitation</td>
</tr>
<tr>
<td></td>
<td>Lung volume reduction</td>
</tr>
</tbody>
</table>
## COPD AND COMORBIDITIES

### OVERALL KEY POINTS:

- **COPD** often coexists with other diseases (comorbidities) that may have a significant impact on disease course.

- In general, the presence of comorbidities should not alter COPD treatment and comorbidities should be treated per usual standards regardless of the presence of COPD.

- Lung cancer is frequently seen in patients with COPD and is a main cause of death.

- Cardiovascular diseases are common and important comorbidities in COPD.

- Osteoporosis, depression/anxiety, and obstructive sleep apnea are frequent, important comorbidities in COPD, are often under-diagnosed, and are associated with poor health status and prognosis.

- Gastroesophageal reflux (GERD) is associated with an increased risk of exacerbations and poorer health status.

- When COPD is part of a multimorbidity care plan, attention should be directed to ensure simplicity of treatment and to minimize polypharmacy.
REFERENCES


